Topical Treatment with Inhibitors of the Phosphatidylinositol 3′-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice

Barbara Bedogni, Melony S. O'Neill, Scott Welford, Donna M. Bouley, Amato J. Giaccia, Nicholas C. Denko, Marianne Broome Powell

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/ Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways inhibited the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive behavior, and reduced angiogenesis. The inhibitor Ly294002, which is specific for phosphatidylinositol 3′-kinase, effectively reduced melanoma cell growth both in vitro and in vivo. Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, reduced invasion, which correlated with reduction of the metalloproteinase matrix metalloproteinase 2. Tumor angiogenesis was disrupted through inhibition of vascular endothelial growth factor production from the tumor cells and antiangiogenic effects on endothelial cells. Observations with TPras melanoma cells that express dominant negative Δp85 or kinase-inactive Raf301 supported the specificity of the phenomena observed with the chemical inhibitors. These studies demonstrate that topical treatment targeting Ras effectors is efficacious, without systemic toxicities, and may prove to be useful in treating and preventing the progression of cutaneous melanoma.

Original languageEnglish (US)
Pages (from-to)2552-2560
Number of pages9
JournalCancer Research
Volume64
Issue number7
DOIs
StatePublished - Apr 1 2004
Externally publishedYes

Fingerprint

Phosphatidylinositol 3-Kinase
SCID Mice
Mitogen-Activated Protein Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Melanoma
MAP Kinase Kinase 2
MAP Kinase Kinase 1
Matrix Metalloproteinase 2
Metalloproteases
Growth
Vascular Endothelial Growth Factor A
Neoplasms
Phosphotransferases
Endothelial Cells
Skin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Topical Treatment with Inhibitors of the Phosphatidylinositol 3′-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice. / Bedogni, Barbara; O'Neill, Melony S.; Welford, Scott; Bouley, Donna M.; Giaccia, Amato J.; Denko, Nicholas C.; Powell, Marianne Broome.

In: Cancer Research, Vol. 64, No. 7, 01.04.2004, p. 2552-2560.

Research output: Contribution to journalArticle

@article{bbb7b044fbd04663bdec64ba7950f8db,
title = "Topical Treatment with Inhibitors of the Phosphatidylinositol 3′-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice",
abstract = "Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/ Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways inhibited the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive behavior, and reduced angiogenesis. The inhibitor Ly294002, which is specific for phosphatidylinositol 3′-kinase, effectively reduced melanoma cell growth both in vitro and in vivo. Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, reduced invasion, which correlated with reduction of the metalloproteinase matrix metalloproteinase 2. Tumor angiogenesis was disrupted through inhibition of vascular endothelial growth factor production from the tumor cells and antiangiogenic effects on endothelial cells. Observations with TPras melanoma cells that express dominant negative Δp85 or kinase-inactive Raf301 supported the specificity of the phenomena observed with the chemical inhibitors. These studies demonstrate that topical treatment targeting Ras effectors is efficacious, without systemic toxicities, and may prove to be useful in treating and preventing the progression of cutaneous melanoma.",
author = "Barbara Bedogni and O'Neill, {Melony S.} and Scott Welford and Bouley, {Donna M.} and Giaccia, {Amato J.} and Denko, {Nicholas C.} and Powell, {Marianne Broome}",
year = "2004",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-03-3327",
language = "English (US)",
volume = "64",
pages = "2552--2560",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Topical Treatment with Inhibitors of the Phosphatidylinositol 3′-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice

AU - Bedogni, Barbara

AU - O'Neill, Melony S.

AU - Welford, Scott

AU - Bouley, Donna M.

AU - Giaccia, Amato J.

AU - Denko, Nicholas C.

AU - Powell, Marianne Broome

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/ Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways inhibited the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive behavior, and reduced angiogenesis. The inhibitor Ly294002, which is specific for phosphatidylinositol 3′-kinase, effectively reduced melanoma cell growth both in vitro and in vivo. Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, reduced invasion, which correlated with reduction of the metalloproteinase matrix metalloproteinase 2. Tumor angiogenesis was disrupted through inhibition of vascular endothelial growth factor production from the tumor cells and antiangiogenic effects on endothelial cells. Observations with TPras melanoma cells that express dominant negative Δp85 or kinase-inactive Raf301 supported the specificity of the phenomena observed with the chemical inhibitors. These studies demonstrate that topical treatment targeting Ras effectors is efficacious, without systemic toxicities, and may prove to be useful in treating and preventing the progression of cutaneous melanoma.

AB - Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/ Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways inhibited the growth of TPras transgenic melanomas in severe combined immunodeficient mice, blocked invasive behavior, and reduced angiogenesis. The inhibitor Ly294002, which is specific for phosphatidylinositol 3′-kinase, effectively reduced melanoma cell growth both in vitro and in vivo. Both Ly294002 and U0126, a mitogen-activated protein kinase kinase 1/2 inhibitor, reduced invasion, which correlated with reduction of the metalloproteinase matrix metalloproteinase 2. Tumor angiogenesis was disrupted through inhibition of vascular endothelial growth factor production from the tumor cells and antiangiogenic effects on endothelial cells. Observations with TPras melanoma cells that express dominant negative Δp85 or kinase-inactive Raf301 supported the specificity of the phenomena observed with the chemical inhibitors. These studies demonstrate that topical treatment targeting Ras effectors is efficacious, without systemic toxicities, and may prove to be useful in treating and preventing the progression of cutaneous melanoma.

UR - http://www.scopus.com/inward/record.url?scp=1942442169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942442169&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3327

DO - 10.1158/0008-5472.CAN-03-3327

M3 - Article

C2 - 15059911

AN - SCOPUS:1942442169

VL - 64

SP - 2552

EP - 2560

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -